CMR Surgical, the Cambridge, UK-based maker of the Versius surgical robot, has agreed a preferred equity investment of about £300m ($400m) from medical technology group Stryker, the two companies announced on October 12, 2026.
The investment gives Stryker an exclusive option to acquire 100% of CMR Surgical's outstanding equity in the future, subject to the terms of the agreement. Stryker will also become the exclusive US sales agent for the Versius portfolio. The deal is subject to regulatory approvals and customary closing conditions.
No valuation was disclosed, and the companies did not say when or at what price Stryker could exercise its option. Andy Pierce, Stryker's group president for medsurg and neurotechnology, will join CMR Surgical's board.
“This strategic alliance is a significant milestone for CMR and a strong endorsement of the technology, clinical experience and global business we have built.”Massimiliano Colella, Chief Executive Officer, CMR Surgical
What CMR Surgical does
CMR Surgical was founded in 2014 and is a privately held company. It develops Versius, a modular robotic system for minimal-access soft-tissue surgery, and its newer Versius Plus. The companies say its modular design gives flexibility across procedures, surgeon access and sites of care, and lets hospitals add robotic surgery within existing operating room workflows.
When it last raised money, in April 2025, CMR said Versius had been used in more than 30,000 surgical cases in more than 30 countries, across colorectal, general, gynaecology, thoracic and urology surgery. It described Versius then as the second most used soft-tissue surgical robot in the world.
CMR also said in 2025 that it was running two clinical trials: a multicentre study of Versius in paediatric surgery and a trial in transoral robotic surgery.
The terms of the alliance
Under the agreement, Stryker will sell the Versius portfolio in the United States, while CMR Surgical continues to lead product development and commercialisation in all other markets. Stryker said the investment will support future innovation and the global commercialisation of the Versius portfolio.
Stryker described soft-tissue robotics as a high-growth area next to its existing endoscopy, visualisation and enabling technologies businesses. Pierce said the company had evaluated the segment for years and called the alliance a disciplined entry into it. He said Stryker chose CMR to help hospitals and ambulatory surgery centres expand robotic surgery across a broad range of procedures.
Business Cloud noted that the structure could lead to a full takeover of the company by Stryker.
The funding so far
In April 2025, CMR Surgical closed a financing round of more than $200m in a mix of equity and debt. It was backed by the company's existing major investors and included a new debt investment from Trinity Capital. CMR said at the time that the money would go towards expanding Versius sales, with a focus on launching in the United States, and towards product development including Versius Plus.
The Stryker deal now gives CMR a US sales partner with an established hospital customer base, as well as fresh capital. Chief executive Massimiliano Colella said Stryker's scale and customer relationships create a significant growth opportunity in the United States.
Company website: cmrsurgical.com